title: Thromboprophylaxis and VTE rates in soldiers wounded in Operation Enduring Freedom and Operation Iraqi Freedom.
abstract: US soldiers suffer catastrophic injuries during combat. We sought to define risk factors and rates for VTE in this population.
  
  
  
  We gathered data each hospital day on all patients injured in Afghanistan or Iraq who were admitted to the Walter Reed Army Medical Center (WRAMC). We analyzed prophylaxis rates and efficacy and identified risk factors for VTE.
  
  
  
  We recorded data on 506 combat casualties directly admitted to WRAMC after medical air evacuation. The average injury severity score for the group was 18.4 ± 11.7, and the most common reason for air evacuation was injury by improvised explosive device (65%). As part of the initial resuscitation, patients received 4.7 ± 9.0 and 4.00 ± 7.8 units of packed RBCs and fresh frozen plasma, respectively, and 42 patients received factor VIIa. Forty-six patients (9.1%) were given a diagnosis of VTE prior to discharge, 18 (3.6%) during air evacuation, and 28 (5.5%) during the hospital stay. In Cox regression analysis, administration of 1 unit of packed RBCs was associated with a hazard ratio (HR) of 1.04 (95% CI, 1.02-1.07; P = .002), and enoxaparin, 30 mg bid, administered subcutaneously for the majority of hospital days was associated with a HR of 0.31 (95% CI, 0.11-0.86; P = .02) for VTE during the hospitalization.
  
  
  
  Patients who suffer traumatic injuries in combat overseas are at high risk for VTE during evacuation and recovery. Those with large resuscitations are at particularly high risk, and low-molecular-weight heparin is associated with a decrease in VTE.
authors.affiliation: Department of Pulmonary, Critical Care, and Sleep Medicine, Walter Reed National Military Medical Center, Bethesda, MD. Electronic address: aholley9@gmail.com.
authors.forename: Aaron B
authors.initials: AB
authors.lastname: Holley
authors.affiliation: Department of Internal Medicine, Walter Reed National Military Medical Center, Bethesda, MD.
authors.forename: Sarah
authors.initials: S
authors.lastname: Petteys
authors.affiliation: Department of Internal Medicine, Walter Reed National Military Medical Center, Bethesda, MD.
authors.forename: Joshua D
authors.initials: JD
authors.lastname: Mitchell
authors.affiliation: Department of Informatics, US Army Medical Research Institute of Infectious Diseases, Frederick, MD.
authors.forename: Paul R
authors.initials: PR
authors.lastname: Holley
authors.affiliation: Department of Pulmonary, Critical Care, and Sleep Medicine, Walter Reed National Military Medical Center, Bethesda, MD.
authors.forename: Jacob F
authors.initials: JF
authors.lastname: Collen
mesh_terms: D000328:Adult; D055826:Afghan Campaign 2001-; D005260:Female; D005500:Follow-Up Studies; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage*; D006772:Hospitals, Military; D006801:Humans; D015994:Incidence; D007279:Injections, Subcutaneous; D054542:Iraq War, 2003-2011; D008297:Male; D008889:Military Personnel; D012189:Retrospective Studies; D012307:Risk Factors; D015996:Survival Rate / Q000639:trends; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology; D054556:Venous Thromboembolism / Q000453:epidemiology / Q000517:prevention & control*
chemical_list: D006495:Heparin, Low-Molecular-Weight